Recruiting PHASE1 INTERVENTIONAL 1-arm NCT06153251

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Conditions Relapsed and/or Refractory Multiple Myeloma

Interventions BMS-986453 Cyclophosphamide Fludarabine

Updated 14 times since 2024 Last updated: Jun 16, 2025 Started: Jan 23, 2024 Primary completion: May 2, 2030 Completion: May 2, 2030

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06153251, this PHASE1 trial focuses on Relapsed and/or Refractory Multiple Myeloma and remains actively recruiting participants. Sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, it has been updated 14 times since 2024, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

14 versions recorded

Sep 2025 — Present [monthly]

Recruiting PHASE1
Jul 2025 — Sep 2025 [monthly]

Recruiting PHASE1
Mar 2025 — Jul 2025 [monthly]

Recruiting PHASE1
Feb 2025 — Mar 2025 [monthly]

Recruiting PHASE1
Jan 2025 — Feb 2025 [monthly]

Recruiting PHASE1

▶ Show 9 earlier versions

Dec 2024 — Jan 2025 [monthly]

Recruiting PHASE1
Oct 2024 — Dec 2024 [monthly]

Recruiting PHASE1
Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE1
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE1
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE1
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE1
Mar 2024 — Jun 2024 [monthly]

Recruiting PHASE1
Feb 2024 — Mar 2024 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Jan 2024 — Feb 2024 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Data source: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Birmingham, United States , Boston, United States , Cologne, Germany , Denver, United States , Duarte, United States , Heidelberg, Germany , Nashville, United States , New Haven, United States , New York, United States , Pamplona, Spain and 7 more locations